Show simple item record

dc.contributor.authorTainio, Markoen
dc.contributor.authorde, Nazelle Audrey Jen
dc.contributor.authorGötschi, Thomasen
dc.contributor.authorKahlmeier, Sonjaen
dc.contributor.authorRojas-Rueda, Daviden
dc.contributor.authorNieuwenhuijse, Mark Jen
dc.contributor.authorde, Sá Thiago Héricken
dc.contributor.authorKelly, Paulen
dc.contributor.authorWoodcock, Jamesen
dc.date.accessioned2016-02-03T15:26:02Z
dc.date.available2016-02-03T15:26:02Z
dc.date.issued2016-05-05en
dc.identifier.citationPreventive Medicine 2016en
dc.identifier.issn0091-7435
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/253627
dc.description.abstractActive travel (cycling, walking) is beneficial for the health due to increased physical activity (PA). However, active travel may increase the intake of air pollution, leading to negative health consequences. We examined the risk–benefit balance between active travel related PA and exposure to air pollution across a range of air pollution and PA scenarios. The health effects of active travel and air pollution were estimated through changes in all-cause mortality for different levels of active travel and air pollution. Air pollution exposure was estimated through changes in background concentrations of fine particulate matter (PM2.5), ranging from 5 to 200 μg/m3. For active travel exposure, we estimated cycling and walking from 0 up to 16 h per day, respectively. These refer to long-term average levels of active travel and PM2.5 exposure. For the global average urban background PM2.5 concentration (22 μg/m3) benefits of PA by far outweigh risks from air pollution even under the most extreme levels of active travel. In areas with PM2.5 concentrations of 100 μg/m3, harms would exceed benefits after 1 h 30 min of cycling per day or more than 10 h of walking per day. If the counterfactual was driving, rather than staying at home, the benefits of PA would exceed harms from air pollution up to 3 h 30 min of cycling per day. The results were sensitive to dose–response function (DRF) assumptions for PM2.5 and PA. PA benefits of active travel outweighed the harm caused by air pollution in all but the most extreme air pollution concentrations.
dc.description.sponsorshipMT and JW: The work was undertaken by the Centre for Diet and Activity Research (CEDAR), a UKCRC Public Health Research Centre of Excellence. Funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, the National Institute for Health Research, and the Wellcome Trust, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. AJN, DRR, MJN, SK and TG: The work was supported by the project Physical Activity through Sustainable Transportation Approaches (PASTA) funded by the European Union's Seventh Framework Program under EC‐GA No. 602624-2 (FP7-HEALTH-2013-INNOVATION-1). The sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. JW is supported by MRC Population Health Scientist fellowship. THS is supported by the Brazilian Science without Borders Scheme (Process number: 200358/2014-6) and the Sao Paulo Research Foundation (Process number: 2012/08565-4).
dc.languageEnglishen
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution 4.0 International*
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectair pollutionen
dc.subjectbicyclingen
dc.subjectwalkingen
dc.subjectphysical activityen
dc.subjectmortalityen
dc.subjectHealth Impact Assessmenten
dc.subjectRisk-Benefit Assessmenten
dc.titleCan air pollution negate the health benefits of cycling and walking?en
dc.typeArticle
dc.provenanceOA-6894
dc.description.versionThis is the final version of the article. It first appeared from Elsevier via http://dx.doi.org/10.1016/j.ypmed.2016.02.002en
prism.endingPage236
prism.publicationDate2016en
prism.publicationNamePreventive Medicineen
prism.startingPage233
prism.volume187en
dc.rioxxterms.funderBritish Heart Foundation
dc.rioxxterms.funderCancer Research UK
dc.rioxxterms.funderEconomic and Social Research Council
dc.rioxxterms.funderMedical Research Council
dc.rioxxterms.funderNational Institute for Health Research
dc.rioxxterms.funderWellcome Trust
dcterms.dateAccepted2016-02-01en
rioxxterms.versionofrecord10.1016/j.ypmed.2016.02.002en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2016-05-05en
dc.contributor.orcidTainio, Marko [0000-0002-0973-2342]
dc.contributor.orcidWoodcock, James [0000-0003-4769-5375]
dc.identifier.eissn1096-0260
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (MR/K021796/1)
pubs.funder-project-idWellcome Trust (087636/Z/08/Z)
pubs.funder-project-idESRC (ES/G007462/1)
pubs.funder-project-idMRC (MR/K023187/1)
pubs.funder-project-idMRC (MR/K025147/1)
cam.orpheus.successThu Jan 30 12:55:19 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International